ALSO NOTED: Ipsen licenses Acapodene; Committee recommends Fragmin; and much more...

> France's Ipsen has agreed to pay $30 million to license GTx's Acapodene for all indications except breast cancer in Europe. Acapodene is in Phase III for cancer prevention. Report [1]

> An FDA advisory committee has recommended that the agency expand the approval of Pfizer's Fragmin to include the prevention of blood clots in cancer patients. Report [2]

> The newly renamed Caden Biosciences raised $5.85 million in venture capital and is moving to Wisconsin. Report [3]

> Metastatix, an Atlanta-based biopharmaceutical company developing small-molecule drugs to treat cancer and HIV, announced today it has raised a $3.6 million Series A financing round. Release [4]

> The Wall Street Journal provides a blow-by-blow account of Bristol-Myers Squibb's disastrous campaign to hold onto Plavix. CEO Peter Dolan comes in for a large portion of the blame. Article [5]

> Sanofi-Aventis has pulled its marketing application for the heart arrhythmia therapy Multaq following last month's FDA rejection and fresh competition from generic Plavix. Report [6]

> Chutes & Ladders: Celsion CEO Lawrence Olanoff has resigned to return to Forest Labs as COO. CFO Anthony Deasey will be interim CEO. Report [7]

> Zestra Laboratories of Charleston, SC has raised $6 million in a private placement. Release [8]

> A federal appeals court has ruled that Mylan Laboratories did not infringe on J&J's patent of a urinary incontinence therapy. Report [9]

And Finally… Better therapies and earlier interventions are helping drive down the rate of deaths from cancer in the United States, with the biggest declines for men. Article [10]